NovaSterilis

03/23/2026

NovaSterilis’ Therapeutics Sterilization Compatibility Guide has been updated with key new data!

Updated entries highlight API and biologic compatibility under sterilization conditions.

Download your NEW copy to optimize sterilization strategies for your advanced : https://bit.ly/45HI7ux

03/20/2026

Contract e-beam introduces recurring costs, shipping delays, and extended turnaround times.

Cost modeling shows that in-house sterilization can actually reduce expenses by over 30%.

Dive into this cost comparison study for tissue banking to learn more: https://bit.ly/4oj7nkj

03/18/2026

This visualization compares material expansion under purge and no-purge conditions.

Direct observation inside the chamber shows how process parameters influence material response.

Learn more about our visualization capabilities for the process: https://bit.ly/3KkJnz8

03/16/2026

Supercritical CO2 sterilization is an effective modality for single-use and reusable medical devices.

This study demonstrates that scCO2 and peracetic acid (PAA) is an effective terminal sterilization modality against resistant bacteria strains.

Explore the findings on additive-assisted lethality: https://bit.ly/40fniXh

03/13/2026

confirms that defined process parameters achieve the required sterility assurance level.

Selecting between overkill, bioburden, and combined BI/bioburden strategies requires balancing microbial control and material sensitivity.

Explore these validation approaches and regulatory considerations: https://bit.ly/3TQ8QD0

03/12/2026

Our Guide has been updated with several new additions!

The latest updates expand compatibility data for materials exposed to sterilization.

Download your updated copy here: https://bit.ly/3pueZIn

03/09/2026

Interest in low-bioburden powder APIs is rising, highlighting opportunities for processing.

Currently, these powders require precise microbial control and careful formulation before .

However, scCO2 can be a suitable terminal sterilization method for a variety of APIs, which can significantly reduce the amount of effort required during the production process.

This article dives into the growing trend in and development. Read more:

Explore how low bioburden powders for terminal sterilization support sterile drug development, improve contamination control, and enable reliable terminal sterilization strategies for complex biopharma products.

03/05/2026

achieves a sterility assurance level of 10-6 across critical microorganisms.

It effectively inactivates bacterial spores, viruses, yeast, and molds.

This technology provides reliable, broad-spectrum while maintaining product integrity.

03/04/2026

face increasing demands for terminal sterility without compromising graft performance.

Radiation and antibiotic washes introduce trade-offs in collagen integrity and contamination risk.

Meanwhile, achieves SAL 10-6 while preserving structural and biochemical properties.

Dive into the accelerating adoption of supercritical CO2:

Learn how supercritical CO₂ sterilization delivers terminal sterility while preserving tissue graft integrity to meet clinician demands.

03/03/2026

Our VP-1000 equipment provides unprecedented insight into the process.

Seeing inside the vessel reveals fluid dynamics, material interactions, and process behavior.

Learn more about our new visualization capabilities: https://bit.ly/4qZsI4H

02/27/2026

Contamination-driven experiment loss can increase cost and delay R&D timelines.

testing verifies your material integrity and functional performance post-sterilization.

It identifies packaging, parameter, and scalability constraints before capital investment. https://bit.ly/4kjEnIt

02/25/2026

Detergent-based compromises ECM structure and bioactive signaling.

This study evaluates a detergent-free scCO2-EtOH approach for heart dECM processing.

Findings showed that the method preserved structural proteins and key angiogenic factors.

Read more about for regenerative therapies: https://bit.ly/3GZuL6X